Advertisement

Allergy Prevention and Therapy

Keywords

Atopic Eczema Allergic Disease Allergy Clin Immunol Mite Allergen Allergen Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abeck D, Ring J (1998) Etablierte medizinische Therapieansätze. In: Ring J (ed) Neurodermitis. Expertise zur gesundheitlichen Versorgung und Vorsorge bei Kindern mit atopischem Ekzem. Ecomed, Landsberg, pp 93–105Google Scholar
  2. 2.
    Abeck D, Werfel S, Brockow K, Ring J (1997) Die Behandlung des atopischen Ekzems im Kindesalter. Hautarzt 48:379–383PubMedGoogle Scholar
  3. 3.
    Altounyan REC (1967) Inhibition of experimental asthma by a new compound disodium cromoglycate — “Intal”. Acta Allerg (Kbh) 22:487–489Google Scholar
  4. 4.
    Anonymous (2000) Doxepin cream for eczema? Drug Ther Bull 38:31–32Google Scholar
  5. 5.
    Barnes PJ (1996) Molecular mechanism of steroid action in asthma. J Allergy Clin Immunol 97: 159–168PubMedGoogle Scholar
  6. 6.
    Barnes W, Piper P, Castello J (1987) The effect of an oral LT antagonist L-649923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 79:816–821PubMedGoogle Scholar
  7. 7.
    Bernhard JD (1994) Itch. McGraw-Hill, PhiladelphiaGoogle Scholar
  8. 8.
    Betts T, Markman D, Debenham S, Mortiboy D, McKevitt T (1984) Effects of two antihistamine drugs on actual driving performance. Br Med J 288:281–282CrossRefGoogle Scholar
  9. 9.
    Bieber T, Ring J (1987) Terfenadin und Kraftfahrzeug-Führung: Eine Placebo-kontrollierte Doppelblind-Studie zum Einfluß verschiedener Anti-histaminika auf das Fahrverhalten. Med Klin 82:683–686Google Scholar
  10. 10.
    Bovet D, Staub AM (1937) Action protectrice des ethers-phénoliques au cours de l’intoxication histaminique. CR Soc Biol (Paris) 124:547–549Google Scholar
  11. 11.
    Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J (2001) New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol 124:326–331PubMedGoogle Scholar
  12. 12.
    Darsow U, Mautner V, Scharein E, Bromm B, Ring J (1997) Der Eppendorfer Juckreizfragebogen. Hautarzt 48:730–733PubMedGoogle Scholar
  13. 13.
    Dorsch W, Ring J (1984) Suppression of immediate and late anti-IgE-induced skin reactions by topically applied alcohol/onion extract. Allergy 39:43–49PubMedGoogle Scholar
  14. 14.
    Dorsch W, Auch E, Powerlowicz P (1987) Adverse effects of acetyl cysteine on human and guinea pig bronchial asthma in vivo and on human fibro-blasts and leukocytes in vitro. Int Arch Allergy Appl Immunol 82:33–39PubMedGoogle Scholar
  15. 15.
    Drake MD, Millikan LE (1995) The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 131:1403–1408PubMedGoogle Scholar
  16. 16.
    Forth H, Henschler D, Rummel W (1987) Allgemeine und spezielle Pharmakologie und Toxikologie, 5th edn. Wissenschaftsverlag, MannheimGoogle Scholar
  17. 17.
    Foulds IS, McKie RM (1981) A double-blind trial of the H2-receptor antagonist cimetidine and the H1-receptor antagonist promethazine hydrochlo-ride in the treatment of atopic dermatitis. Clin Allergy 11:319PubMedGoogle Scholar
  18. 18.
    Hanifin JM (1991) Atopic dermatitis: New therapeutic considerations. J Am Acad Dermatol 24:1097–1101PubMedGoogle Scholar
  19. 19.
    Fjellner B, Hägermark Ö (1979) Pruritus in poly-cythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 59:505–512PubMedGoogle Scholar
  20. 20.
    Hansel TT, Barnes PJ (eds) (2001) New drug for asthma, allergy and COPI. Progr Resp Res 31. Karger, BaselGoogle Scholar
  21. 21.
    Hatz HJ (1998) Glucocorticoide. Immunologische Grundlagen, Pharmakologie und Therapierichtlinien. Wiss. Verlagsges., StuttgartGoogle Scholar
  22. 22.
    Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J (1980) A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A 77:2533–2536PubMedGoogle Scholar
  23. 23.
    Hoffman C, Schatz M, Harden K, Forsythe A, Chillingar L, Porreco R, Benenson A, Sperling W, Kagnoff M, Saunders B, Zeiger R (1986) The safety of inhaled bronchodilators (IB) during pregnancy. J Allergy Clin Immunol 77:249Google Scholar
  24. 24.
    Kaiser H (1977) Cortisonderivate in Klinik und Praxis. Thieme, StuttgartGoogle Scholar
  25. 25.
    Klein PA, Clark RAF (1999) An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 135:1522–15625PubMedGoogle Scholar
  26. 26.
    Künig W, Baron M, Ehring F (1984) Effect of calcium mineral solutions on the histamine release from human peripheral leukocytes. Arzneimit-telforschung 34:52–54Google Scholar
  27. 27.
    Kunkel G, Schupp J, Borner K, Lasius D, Meysel U (1983) Untersuchungen zur Theophyllinwirkung unter besonderer Berücksichtigung der Tagesrhythmik. Therapiewoche 33:1113–1123Google Scholar
  28. 28.
    Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O’Byrne PM (1990) Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 antagonist. N Engl J Med 323:1736–1739PubMedCrossRefGoogle Scholar
  29. 29.
    Martin U, Römer D (1977) Ketotifen: A histamine release inhibitor. Monogr Allergy 12:145–149PubMedGoogle Scholar
  30. 30.
    Mazurek N, Berger G, Pecht I (1980) Binding site on mast cells and basophils for the antiallergic drug cromolyn. Nature 286:722–724PubMedGoogle Scholar
  31. 31.
    Melin L, Frederikson T, Noren P, Swebilius BG (1986) Behavioural treatment of scratching in patients with atopic dermatitis. Br J Dermatol 115: 467–474PubMedGoogle Scholar
  32. 32.
    Middleton ER Jr (1985) New drugs in management: calcium antagonists. Chest 87:79Google Scholar
  33. 33.
    Newton R (2001) Molecular mechanisms of glucocorticoid action. What is important? Thorax 55:603–613Google Scholar
  34. 34.
    Nolte D, Krejci G (1983) Methylxanthine beich. Apotheker-Verlag, StuttgartGoogle Scholar
  35. 35.
    Ring J, Brockow K, Abeck D (1996) The therapeutic concept of “patient management” in atopic eczema. Allergy 51:206–215PubMedGoogle Scholar
  36. 36.
    Ring J, Fröhlich HH (1985) Wirkstoffe in der dermatologischen Therapie, 2nd edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  37. 37.
    Schmutzler W (1981) Möglichkeiten der Arzneitherapie allergischer Erkrankungen. Pharmakotherapie 4:155–162Google Scholar
  38. 38.
    Schmutzler W, Delmich K, Eichelberg D, Glück S, Greven T, Jürgensen H, Riesener KP, Risse G, Pult P (1985) The human adenoidal mast cell susceptibility to different secretagogues and secretion inhibitors. Int Arch Allergy Appl Immunol 77: 177–178PubMedGoogle Scholar
  39. 39.
    Simons KI, Simons FER (1996) H1-receptor antagonists: Pharmacokinetics and clinical pharmacology. In: Simons FER (ed) Histamine and H1-receptor antagonists in allergic disease. Dek-ker, New York, 175–213Google Scholar
  40. 40.
    Wassilew SW (2000) Serotoninantagonisten bei Pruritis. In: Plewig G, Degitz K (eds) Fortschritte der praktischen Dermatologie und Venerologie. Springer, Berlin Heidelberg New York, pp 437–440Google Scholar
  41. 41.
    Weinberger MM, Bronsky EA (1974) Evaluation of oral bronchodilator therapy in asthmatic children. J Pediatr 84:421PubMedGoogle Scholar
  42. 42.
    Woodward JK, Munro NL (1982) Terfenadine, the first non-sedating antihistamine. Arzneimittel-forschung/Drug Res 32:1154–1159Google Scholar

References

  1. 1.
    Aas K (1975) Clinical and experimental aspects of purification and standardization of allergen extracts. Int Arch Allergy Appl Immunol 49:44PubMedGoogle Scholar
  2. 2.
    Abramsom MJ, Puy RM, Weiner JM (1995) Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 151:969–974Google Scholar
  3. 3.
    Akdis CA, Blaser K (2000) Mechanisms of allergen-specific immunotherapy. Allergy 55:522–530PubMedGoogle Scholar
  4. 4.
    André C, Vatrinet C, Galvain S, Carat F, Sicard H (2000) Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 121:229–234PubMedGoogle Scholar
  5. 5.
    Asero R (2000) Fennel, cucumber, and melon allergy successfully treated with pollen-specific injection immunotherapy. Ann Allergy Asthma Immunol 84:460–462PubMedCrossRefGoogle Scholar
  6. 6.
    Bauer CP, Czettritz G v, Weinmann HM (1984) Zerebrales Anfallsleiden — eine Kontra-Indikation für die Hyposensibilisierung? Allergologie 7: 161–162Google Scholar
  7. 7.
    Baumgarten C (1978) Häufigste Nebenwirkungen bei der spezifischen Hyposensibilisierung. Allergologie I:223–228Google Scholar
  8. 8.
    Berbis Ph, Carena MC, Auffranc JC, Privat Y (1986) Vascularite necrotisante cutaneo-systemique survenue en cours de desensibilisation. Ann Derm Venereol 113:805–809PubMedGoogle Scholar
  9. 9.
    Blaser K (2001) Immunologische Grundlagen der spezifischen Hyposensibilisierung. In: Ring J, Darsow U (eds) Allergie 2000. Dustri, Munich, pp 269–274Google Scholar
  10. 10.
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, André C (1999) Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54:249–260PubMedGoogle Scholar
  11. 11.
    Braun W (1980) Hyposensibilisierung: Bericht über einen Todesfall in der Praxis. Therapiewoche 30:2215–2216Google Scholar
  12. 12.
    Brede HD, Aas K (eds) (1979) Allergen-Extrakte. Fischer, StuttgartGoogle Scholar
  13. 13.
    Büchner K, Siepe M ((1995) Nutzen der Hyposensibilisierung unter wirtschaftlichen Aspekten. Allergo J 4:156–163Google Scholar
  14. 14.
    Casimir G, Gossart B, Vis HL, Duchateau J (1985) Antibody against beta-lactoglobulin (IgG) and cow’s milk allergy, J Allergy Clin Immunol 75:207Google Scholar
  15. 15.
    Clavel R, Bousquet J, André C (1989) Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53:493–498Google Scholar
  16. 16.
    Creticos PS, Naclerio RM, Adkinson NF, Norman PS (1990) Efficacy, safety and kinetics of oral ragweed immunotherapy in the treatment of allergic seasonal rhinitis (Abstract). J Allergy Clin Immunol 85:165Google Scholar
  17. 17.
    Debelic M (1978) Behandlungserfolge mit Halb-Depot-Extrakten. In: Gronemeyer W, Fuchs E (eds) Allergosen der Atemwege. Dustri, Munich, 78 ffGoogle Scholar
  18. 18.
    Drachenberg KJ, Wheeler AW, Stuebner P, Horak F (2001) A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56: 498–505PubMedGoogle Scholar
  19. 19.
    Düngemann H (1978) Karenz-Expositionsprophylaxe. Atemwegs-u Lungenkr 4:7Google Scholar
  20. 20.
    Durham SR, Walker SM, Varga EM, et al. (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468–475PubMedGoogle Scholar
  21. 21.
    Ebner C (1999) Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 119:1–5PubMedGoogle Scholar
  22. 22.
    Frankland AW (1980) Anaphylactic reaction to desensitization. Br Med J 281:1429Google Scholar
  23. 23.
    Freeman EJ (1914) Vaccination against hay fever. Lancet 1:1178Google Scholar
  24. 24.
    Fuchs AM, Strauss MB (1959) The clinical evaluation and preparation and standardization of a new water-insoluble whole ragweed pollen complex. J Allergy 30:66PubMedGoogle Scholar
  25. 25.
    Fuchs E (1972) Praktische Durchführung einer spezifischen Hyposensibilisierung. Med Klin 67: 988PubMedGoogle Scholar
  26. 26.
    Georgitis JW, Nickelsen JA, Wypych JI, Barde SH, Clayton WF, Reisman RE (1986) Local intranasal immunotherapy with high-dose polymerizid ragweed extract. Int Arch Allergy Appl Immunol 81:170–173PubMedGoogle Scholar
  27. 27.
    Grewe M (2000) Hyposensibilisierung bei atopischem Ekzem. Allergo J 9:351–53Google Scholar
  28. 28.
    Gronemeyer W, Fuchs E (eds) (1983) Karenz und Hyposensibilisierung bei Inhalations-und Insektengift-Allergie, 2nd edn. Dustri, MunichGoogle Scholar
  29. 29.
    Horak F, Stubner P, Berger UE, Marks B, Toth J, Jäger S (1998) Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Invest Allergol Clin Immunol 8:165–171Google Scholar
  30. 30.
    Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM (1978) A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299:157PubMedCrossRefGoogle Scholar
  31. 31.
    Jacobsen L, Dreborg S, Moller C, Valovirta E, Wahn U, Niggemann B, Koller D, Urbanek R, Halken S, Host A, Lowenstein H (1996) Immunotherapy as a preventive allergy treatment (abstract). J Allergy Clin Immunol 97:232Google Scholar
  32. 32.
    Jarisch R, Götz Aberer W (1988) Side effects of specific immunotherapy, reduction by pretreatment with antihistamines. J Allergy Clin Immunol 83:262Google Scholar
  33. 33.
    Jarisch R, Wöhrl S, Focke M, Hemmer W (2001) Anaphylaktische Reaktion bei spezifischer Immuntherapie durch Diaminoxidasehemmung nach Azetylzystein-Therapie. Allergologie 24: 112–115Google Scholar
  34. 34.
    Johansson SGO, Miller ACML, Overell BG, Wheeler AW (1974) Grass pollen-tyrosine adsorbate. Clin Allergy 4:57PubMedGoogle Scholar
  35. 35.
    Jung CM, Funk A, Rakoski J, Ring J (1997) Immunohistochemical analysis of late local skin reactions during rush venom immunotherapy. Allergy 52:717–726PubMedGoogle Scholar
  36. 36.
    Kasai M, Kurasawa K, Nakajima H, Iwamoto I (2001) T cell vaccination eliminates antigen-specific T cells and prevents antigen-induced eosinophil recruitment into the tissue. Int Arch Allergy Immunol 125[Suppl 1]:59–66PubMedGoogle Scholar
  37. 37.
    Kleinhans D, Zöller I (2000) Therapiestudien zur sublingualen Immuntherapie mit Allergenen. Eine aktuelle Bestandsaufnahme. Allergologie 23:349–353Google Scholar
  38. 38.
    Krieg AM, Hartmann G, Yi AK (2000) Mechanism of action of CpG DNA (review). Curr Top Microbiol Immunol 247:1–21PubMedGoogle Scholar
  39. 39.
    Lessof M, Sobotka AK, Lichtenstein LM (1976) Protection against anaphylaxis in hymenoptera sensitive patients by passive immunization. J Allergy Clin Immunol 57:246Google Scholar
  40. 40.
    Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC (1987) Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 79:660–677PubMedGoogle Scholar
  41. 41.
    Lockey RF, Bukantz SC (eds) (1999) Allergens and allergen immunotherapy, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
  42. 42.
    Lowell F, Frankling W (1965) A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 273:675–679PubMedCrossRefGoogle Scholar
  43. 43.
    Løwenstein H (1986) Standardization of allergen extracts. In: Ring J, Burg G (eds) New trends in allergy II. Springer, Berlin Heidelberg New York, pp 266 292Google Scholar
  44. 44.
    Märtens P, Lobermeyer K (2001) Krankheitskosten-Studie und Kosten-Nutzen-Analyse der spezifischen Immuntherapy bei Asthma. Allergo J 10:341–347Google Scholar
  45. 45.
    Malling H-J (2001) Allergen-specific immunotherapy in allergic rhinitis. Curr Opin Allergy Clin Immunol 1:43–46PubMedGoogle Scholar
  46. 46.
    Marsh DG, Lichtenstein LM, Campbell DH (1970) Studies on allergoids prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group component. Immunology 18:705–722PubMedGoogle Scholar
  47. 47.
    Metzger WJ, Turner E, Patterson R (1978) The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 61:268–272PubMedGoogle Scholar
  48. 48.
    Mueller DL, Jenkins MK (199) Molecular mechanisms underlying functional T cell unresponsiveness. Curr Opinion Immunol 7:375–381Google Scholar
  49. 49.
    Nelson HS, Iklé D, Buchmeier A (1996) Studies of allergen extract stability: The effects of dilution and mixing. Mosby Year Book, St. Louis, p 382Google Scholar
  50. 50.
    Noon L (1911) Prophylactic inoculation against hay-fever. Lancet 1572Google Scholar
  51. 51.
    Norman PS (1980) An overview of immunotherapy. J Allergy Clin Immunol 65:87PubMedGoogle Scholar
  52. 52.
    Norman PS, et al. (1996) Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 154:1623–1628PubMedGoogle Scholar
  53. 53.
    Oppenheimer J, Areson JG, Nelson HS (1994) Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 93:61–67PubMedGoogle Scholar
  54. 54.
    Passalacqua G, Albano M, Fragonese L, et al. (1998) Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351:629–632PubMedGoogle Scholar
  55. 55.
    Phanuphak P, Kohler PF (1980) Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 68:479–485PubMedGoogle Scholar
  56. 56.
    Przybilla B, Ring J, Galosi A, Geursen RG, Stickl HA (1986) Bee-venom immunoglobulin for prophylaxis of anaphylactic reactions during bee venom immunotherapy (rush hyposensitization). Immunol Allergy Practice 8:107–111Google Scholar
  57. 57.
    Przybilla B, Ring J, Grießhammer B, Braun-Falco O (1987) Schnellhyposensibilisierung mit Hyme-nopterengiften — Verträglichkeit und Therapieerfolg. Dtsch Med Wochenschr 112:416–424PubMedCrossRefGoogle Scholar
  58. 58.
    Punnonen J (2000) Molecular breeding of allergy vaccines and antiallergic cytokines. Int Arch Allergy Immunol 121:173–182PubMedGoogle Scholar
  59. 59.
    Rakoski J, Wessner D (2001) A short assessment of sublingual immunotherapy. Int Arch Allergy Immunol 126:185–187PubMedGoogle Scholar
  60. 60.
    Ring J, Bode U, Kadach U, Stix E, Burg G (1983) Gammaglobuline und Allergie. Klinische Ergebnisse einer kontrollierten Studie mit Standard-Immunglobulin G und Plazebo bei Pollinosis. Münch Med Wochenschr 125:289–292Google Scholar
  61. 61.
    Ring J (1987) Spezifische Hyposensibilisierung. Wirkungsmechanismen, Erfolge und Probleme. Allergologie 10:392–403Google Scholar
  62. 62.
    Ring J (1982) Successful hyposensitization treatment in atopic dermatitis: results of a trial in monozygotic twins. Br J Dermatol 107:597–602PubMedGoogle Scholar
  63. 63.
    Ring J (1993) Spezifische Hyposensibilisierung bei atopischem Ekzem. Allergo J 2:1–2Google Scholar
  64. 64.
    Ring J, Przybilla B, Bongardts J (1988) Safety of hyposensitization. In: Proceedings of the annual meeting of the EAACI, Plama de Mallorca, 22–26 April 1987. Abello, Madrid, pp 131–138Google Scholar
  65. 65.
    Schadewaldt H (1979–1982) Geschichte der Allergie, vols 1–4. Dustri, München-DeisenhofenGoogle Scholar
  66. 66.
    Schramm G, Kahler H, Suck R, et al. (1999) ‘Allergen engineering’: Variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. Immunology 162:2406–2414Google Scholar
  67. 67.
    Sehon AH, Lee WY (1981) Suppression of IgE antibodies with tolerogenic derivates of allergens. In: Ring J, Burg G (eds) New trends in allergy. Springer, Berlin Heidelberg New York, p 294Google Scholar
  68. 68.
    Taylor G, Shivalkar PR (1972) Local nasal desensitization in allergic rhinitis. Clin Allergy 2:125PubMedGoogle Scholar
  69. 69.
    Turkeltaub PC, Marsh DG, Lichtenstein LM, Norman PS (1978) Development of long-lasting immediate hypersensitivity in nonatopic volunteers parenterally immunized with a purified grass pollen extract. J Allergy Clin Immunol 61:171Google Scholar
  70. 70.
    Ulrich JT, Myers KR (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Powell MF, Newman MJ (eds) Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, pp 495–524Google Scholar
  71. 71.
    Umetsu DT, Hahn JS, Perez-Atayde AR, Geba RS (1985) Serum sickness triggered by anaphylaxis. A complication of immunotherapy. J Allergy Clin Immunol 76:713–718PubMedGoogle Scholar
  72. 72.
    Urbanek R, Karitzky D, Forster J (1978) Die Hyposensibilisierungsbehandlung mit reinem Bienengift. Dtsch Med Wochenschr 103:1656PubMedGoogle Scholar
  73. 73.
    Valenta R, Kraft D (1995) Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 7:751–756PubMedGoogle Scholar
  74. 74.
    Vervloet D, Khairallah E, Arnaud A, Charpin J (1980) A prospective national study of the safety of immunotherapy. Clin Allergy 10:59–64PubMedGoogle Scholar
  75. 75.
    Wahn U, Rebien W (1979) Ergebnisse der oralen Hyposensibilisierung bei kindlichen Pollenallergikern. Pädiat Prax 21:455Google Scholar
  76. 76.
    Wheeler AW, Woroniecki SR (2001) Immunological adjuvants in allergy vaccines: Past, present and future. Allergology Int 50:295–301Google Scholar
  77. 77.
    Wilson DR, Nouri-Aria KT, Walker SM, Pajno GB, O’Brien F, Jacobson MR, Mackay IS, Durham SR (2001) Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 107:971–976PubMedGoogle Scholar
  78. 78.
    Wortmann F (1976) Zur oralen Desensibilisierung von Inhalationsallergien bei Kindern. Mschr Kinderheilk 124:218PubMedGoogle Scholar
  79. 79.
    Wüthrich B ((1977) Zur spezifischen Hyposensibilisierung der Pollinosis. Schweiz Rundsch Med 66:260Google Scholar
  80. 80.
    Yang WH, Dorval G, Osterland CK, Gilmore NJ (1979) Circulating immune complexes during immunotherapy. J Allergy Clin Immunol 63: 305–307Google Scholar
  81. 81.
    Zachariae H, Cramers M, Herlin T, Jensen J, Kragbale K, Ternowitz T, Thestrup-Petersen K (1985) Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol (Stockh) [Suppl] 114:48–54Google Scholar
  82. 82.
    Zimmermann S, Egeter O, Hausmann S, Lipford GB, Röcken M, Wagner H, Heeg K (1998) CpG oligodeoxynucleotides trigger, protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627–3630PubMedGoogle Scholar

Positions Papers

  1. 83.
    World Health Organization (WHO) Bousquet J, Lockey RF, Malling HJ, et al. (1998) WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53[Suppl 44]:1–42Google Scholar
  2. 84.
    European Academy of Allergy and Clinical Immunology (EAACI) Bousquet J, Müller UR, Dreborg S, et al. (1987) Immunotherapy with Hymenoptera venoms. Allergy 42:40–413Google Scholar
  3. 85.
    Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E, et al. (1998) Local immunotherapy. Position paper by the Working Group on Local Immunotherapy of the EAACI Subcommittee and the ESPACI Immunotherapy Subcommittee. Allergy 53:933–944PubMedGoogle Scholar
  4. 86.
    Ärzteverband Deutscher Allergologen (ÄDA) Sennekamp J, Kersten W, Hornung B (1995) Empfehlungen zur Hyposensibilisierung mit Allergenextrakten. Allergo J 4:205–212Google Scholar
  5. 87.
    Deutsche Gesellschaft für Allergologie und klinische Immunologie (DGAI) Kleine-Tebbe J, Fuchs T, Klimek L, et al. (2000) Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Positionspapier der DGAI, inhaltlich abgestimmt mit dem ÄDA. Allergo J 6 (in press)Google Scholar

References

  1. 1.
    Abraham RT (1998) Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10:330–336PubMedGoogle Scholar
  2. 2.
    Brendel W, Ring J, Seifert J (1974) Experimental and clinical aspects of ALG. Progr Immunol II 5:245–252Google Scholar
  3. 3.
    Busse W, Corren J, Lanier BQu, McAlary M, Fowler-Taylor A, Della Cioppa G, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184–190PubMedGoogle Scholar
  4. 4.
    Hansel TI, Barnes PJ (eds) (2001) New drugs for asthma, allergy and COPD. Karger, BaselGoogle Scholar
  5. 5.
    Heusser C, Jardieu P (1997) Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 9: 805–814PubMedGoogle Scholar
  6. 6.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kaszica J, Schwieterman WD, Siegel JJN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098–1104PubMedGoogle Scholar
  7. 7.
    Jardieu PM, Fick RB Jr (1999) IgE inhibitors as a therapy for allergic disease. Int Arch Allergy Immunol 118:112–115PubMedGoogle Scholar
  8. 8.
    Krieg AM (1996) An innate immune defence mechanism based on the recognition of CpG motifs in microbial DANN. J Lab Clin Med 128: 128–133PubMedGoogle Scholar
  9. 9.
    Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CM, Cowley D, Hansel T, Djukanovic R, Sterk PJ, Holgate S, Barnes PJ (1999) SB 240563, a humanised anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma. Am J Resp Crit Care Med 159:A624Google Scholar
  10. 10.
    Losman JA, Chen XP, Hilton D, Rothman P (1999) SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol 162:3770–3774PubMedGoogle Scholar
  11. 11.
    Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966–1973PubMedGoogle Scholar
  12. 12.
    Prinz B, Nachbar T, Plewig G (1994) Treatment of severe atopic dermatitis with extracorporal photophoresis. Arch Dermatol Res 287:48–52PubMedGoogle Scholar
  13. 13.
    Reitamo S (2001) Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 107:445–448PubMedGoogle Scholar
  14. 14.
    Renz H, Bradley K, Enssel K, Loader JE, Larsen GL, Gelfand EW (1996) Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness in vivo with soluble IL-4 receptors. Int Arch Allergy Immunol 106:167Google Scholar
  15. 15.
    Ring J, Seifert J, Lob G, Coulin K, Angstwurm H, Frick E, Brass B, Mertin J, Backmund H, Brendel W (1974) Intensive immunosuppression in the treatment of multiple sclerosis. Lancet 2:1093–1095PubMedGoogle Scholar
  16. 16.
    Sacher R, FRCPC, and the IVIG Advisory Panel (2001) Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108:S139–146PubMedGoogle Scholar
  17. 17.
    Saint-Remy J-MR (1999) Allergisches Bronchialasthma: Immuntherapie durch Antikörper. Die gelben Hefte 39:59Google Scholar
  18. 18.
    Szczeklik A, Nizankowska E, Dworski R, Domagala B, Pinis G (1991) Cyclosporine for steroid dependent asthma. Allergy 46:312–315PubMedGoogle Scholar
  19. 19.
    Tony H-P, Shen B-J, Reusch P, Sebald W (1994) Design of human interleukin-4 antagonists to inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T cells and B cells with high efficiency. Eur J Biochem 225:659–665PubMedGoogle Scholar

References

  1. 1.
    Bock KD (1993) Wissenschaftliche und alternative Medizin. Springer, Berlin Heidelberg New YorkGoogle Scholar
  2. 2.
    Davenas E, Beauvais F, Amara J, et al. (1988) Human basophil degranulation triggered by very dilute antiserum against IgE. Nature 333:816–818PubMedGoogle Scholar
  3. 3.
    De Weck AL (2000) From basic science to complementary medicine. ACI Int 13:5–6Google Scholar
  4. 4.
    Dorsch W, Ring J (2002) Komplementärmethoden bzw. sog. “Alternativmethoden” in der Aller-gologie. Allergo J 11:163–170Google Scholar
  5. 5.
    Dorsch W (1996) Alternative Heilmethoden in der Allergologie? Allergo J 5:388–393Google Scholar
  6. 6.
    Fulder SJ, Munro RE (1985) Complementary medicine in the United Kingdom: Patients, practitioners, and consultations. Lancet II:542–545Google Scholar
  7. 7.
    Fung KP, Chow O, So SY (1986) Attenuation of exercise-induced asthma by acupuncture. Lancet II:1419–1422Google Scholar
  8. 8.
    Köbberling J (1997) Der Wissenschaft verpflichtet. Med Klin 92:171–190Google Scholar
  9. 9.
    Kofler H, Ulmer H, Mechter E, Falk M, Fritsch PO (1996) Bioresonanz bei Pollinose: Eine vergleichende Untersuchung zur diagnostischen und therapeutischen Wertigkeit. Allergologie 19:114–122Google Scholar
  10. 10.
    Kukutsch NA (1997) Darstellung und Diskussion alternativer/komplementärer diagnostischer und/oder therapeutischer Konzepte im Hinblick auf atopische Erkrankungen. Dissertation, HamburgGoogle Scholar
  11. 11.
    Lambeck M (2001) Eine Revolution der Physik? Die Unterstützung der Homöpathie und ähnlicher Therapieeinrichtungen durch die Krankenkassen. Skeptiker 14:117–122Google Scholar
  12. 12.
    Lüdtke R, Kunz B, Seeber N, Ring J ((2001) Test-retest reliability and validity of the kinesiology muscle test. Complement Ther Med 9:141–145PubMedGoogle Scholar
  13. 13.
    Oepen I, Prokop O (1985) Außenseitermethoden in der Medizin. Wissenschaftl. Buchgesellschaft, DarmstadtGoogle Scholar
  14. 14.
    Miller MJS, Vergnolle N, McKnight W, et al. (2001) Inhibition of neurogenic inflammation by the Amazonian herbal medicine Sangre del Grado. J Invest Dermatol 117:725–730PubMedGoogle Scholar
  15. 15.
    Ring J, Behrendt H, Vieluf D (eds) (1997) New trends in allergy IV. Springer, Berlin Heidelberg New YorkGoogle Scholar
  16. 16.
    Ring J (ed) (1998) Neurodermitis. Expertise zur gesundheitlichen Versorgung und Vorsorge bei Kindern mit atopischem Ekzem. Ecomed, LandsbergGoogle Scholar
  17. 17.
    Schäfer T, Riehle A, Wichmann HE, Ring J (2002) Alternative medicine in allergies — prevalence, patterns of use, and costs. Allergy 57:684–700Google Scholar
  18. 18.
    Schöni MH, Nikolaizik WH, Schöni-Afolter F (1997) Efficacy trial of bioresonance in children with atopic dermatitis. Int Arch Allergy Immunol 112:238–246PubMedGoogle Scholar
  19. 19.
    Sheehan MP, Atherton DJ (1992) A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 126:179–184PubMedGoogle Scholar
  20. 20.
    Siebenwirth J, Rakoski J (1997) Klassisch-homö-opathische Therapie bei Neurodermitis. Hautarzt 48[Suppl 1]:S22Google Scholar
  21. 21.
    Stiftung Warentest (ed) (1996) Handbuch Die andere Medizin. Nutzen und Risiken sanfter Heilmethoden, 4th edn. Stiftung Warentest, BerlinGoogle Scholar
  22. 22.
    Wiesenauer M, Gaus W, Häussler S (1990) Behandlung der Pollinosis mit Galphimia glauca. Allergologie 13:359–363Google Scholar
  23. 23.
    Wong HCG (2001) Chinese herbal medicine and allergy. ACI Int 13:192–196Google Scholar
  24. 24.
    Wüthrich B (1999) Allergologie: Quo vadis? Schweiz Med Wochenschr 129:905–914PubMedGoogle Scholar

References

  1. 1.
    Arlian LG, Platts-Mills TAE (2001) The biology of dust mites and the remediation of mite allergens in allergic disease. J Allergy Clin Immunol 107:S406–413PubMedGoogle Scholar
  2. 2.
    Behrendt H, et al. (1999) Der Rat von Sachverständigen für Umweltfragen. Umwelt und Gesundheit. Risiken richtig einschätzen. Sondergutachten. Metzler-Poeschel, StuttgartGoogle Scholar
  3. 3.
    Bergmann K-Ch (2001) Allergenkarenz bei allergischem Asthma. In: Ring J, Darsow U (eds) Allergie 2000. Dustri, Munich, pp 164–168Google Scholar
  4. 4.
    Bischoff E, Krause-Michel B, Nolte D (1986) Zur Bekämpfung der Hausstaubmilben in Haushalten von Patienten mit Milbenasthma. Allergologie 9:448–457Google Scholar
  5. 5.
    Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M (2001) Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 108:516–520PubMedGoogle Scholar
  6. 6.
    Boehm G, Leuschner RM (eds) (1987) Advances in aerobiology. Experientia [Suppl] 51:197–202Google Scholar
  7. 7.
    Borelli S (1997) Deutsche Klinik für Dermatologie und Allergie Davos (Alexanderhausklinik) 1960–1995. Stiftung Derm All Forschung, DavosGoogle Scholar
  8. 8.
    Bucher H, Gutzwiller F (eds) (1993) Checkliste Gesundheitsberatung und Prävention. Thieme, StuttgartGoogle Scholar
  9. 9.
    Cloosterman SGM, Schermer TRJ, Bijl-Hofland ID, et al. (1999) Effects of house dust mite avoidance measures on Der p1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clin Exp Allergy 29:1336–1346PubMedGoogle Scholar
  10. 10.
    Colloff MJ, Ayres J, Carswell F, Howarth PH, Merret TG, Mitchell EB, Walshaw MJ, Warner JO, Warner JA, Woodcock AA (1992) The control of allergens of dust mite and domestic pets: a position paper. Clin Exp Allergy 22[Suppl 2]:1–28PubMedGoogle Scholar
  11. 11.
    Colloff MJ, Taylor C, Merrett TG (1995) The use of domestic steam cleaning for the control of house dust mites. Clin Exp Allergy 25:1061–1066PubMedGoogle Scholar
  12. 12.
    DGAI-Stellungnahme: Ring J et al. (1993) Allergie-Prävention. Allego J 2:36–37Google Scholar
  13. 13.
    Diebschlag W, Diebschlag B (2000) Hausstauballergien. Gesundheitliche und hygienische Aspekte, 2nd edn. Herbert Utz Verlag, MunichGoogle Scholar
  14. 14.
    Disch R, Schöne D (1995) Prävention in der Dermatologie. Präv Rehabil 3:155–160Google Scholar
  15. 15.
    Eggleston PA, Bush RK (2001) Environmental allergen avoidance: An overview. J Allergy Clin Immunol 107:S403–405PubMedGoogle Scholar
  16. 16.
    Ehnert B, Lau-Schadendorf S, Weber A, et al. (1992) Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 90:135–138PubMedGoogle Scholar
  17. 17.
    Ewers U, Kainka E, Umbach KH, Diebschlag W (2000) Methoden zur Überprüfung der Qualitätsanforderungen an milbenallergendichte Matratzen-und Bettbezüge (Encasings). Allergo J 9:261–26Google Scholar
  18. 18.
    ETAC Study Group (1998) Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 9:116–124Google Scholar
  19. 19.
    Fröschl M (2000) Gesund sein. Integrative Gesund-Seins-Förderung als Ansatz für Pflege, soziale Arbeit und Medizin. Lucius u. Lucius, StuttgartGoogle Scholar
  20. 20.
    Gieler U, Niemeier V, Kupfer J, Brosig B (2001) Psychosomatische Konzepte in der Allergologie. In: Ring J, Darsov U (eds) Allergie 2000. Dustri, Munich, pp 189–192Google Scholar
  21. 21.
    Götzsche PC, Hammarquist C, Burr M (1998) House dust mite control measures in the management of asthma: meta-analysis. BMJ 317:1105–1110PubMedGoogle Scholar
  22. 22.
    Grootendorst DC, Dahlén S-E, van den Bos JW, Duiverman EJ, Veselic-Charvat M, Vrijlandt EJLE, O’sullivan S, Kumlin M, Sterk PJ, Roldaan AC (2001) Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin Exp Allergy 31:400–408PubMedGoogle Scholar
  23. 23.
    Huss K, Squire EN Jr, Carpenter GB, Smith LJ, Huss RJ, Salata K, Salerno M, Agostinelli D, Hershey J (1992) Effective education of adults with asthma who are allergic to dust mites. J Allergy Clin Immunol 89:836–843PubMedGoogle Scholar
  24. 24.
    Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S ((2000) Probiotics in the management of atopic eczema. Clin Exp Allergy 30:1604–1610PubMedGoogle Scholar
  25. 25.
    Johansson SGO, Haahtela T (eds) (2000) Prevention of allergy and asthma. Interim report. Based on the WHO/IAACI Meeting on the Primary Prevention of Allergy and Asthma. Allergy 55:1069–1088Google Scholar
  26. 26.
    Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357:1076–1079PubMedGoogle Scholar
  27. 27.
    Kjellman N-I M, Nilsson L (1999) Is allergy prevention realistic and beneficial? Pediatr Allergy Immunol 10[Suppl 12]:11–17PubMedGoogle Scholar
  28. 28.
    Kniest FM, Liebenberg B, Ahr A (1992) Mattress-encasings as a barrier for mites and airborne dust. J Aerosol Sci 23[Suppl I]:S551–554Google Scholar
  29. 29.
    Korsgaard J (1982) Preventive measures in housedust allergy. Am Rev Respir Dis 125:80–84PubMedGoogle Scholar
  30. 30.
    Kroidl RF (1992) Allergie gegen Hausstaubmilben: Sanierungsmaßnahmen: Konventionell? Mit akariziden Mitteln? Allergologie 15:197–201Google Scholar
  31. 31.
    Lau S, Falkenhorst G, Weber A, Werthman I, Lind P, Buettner-Goetz P, Wahn U (1989) High mite-allergen exposure increases the risk of senzitization in atopic children and young adults. J Allergy Clin Immunol 84:718–725PubMedGoogle Scholar
  32. 32.
    Liccardi G, Custovic A, Cazzola M, Russo M, D’Amato M, D’Amato G (2000) Avoidance of allergens and air pollutants in respiratory allergy. Allergy 56:705–722Google Scholar
  33. 33.
    Medici TC, Radielovic P, Morley J (1989) Ketotifen in the prophylaxis of extrinsic bronchial asthma. A multicenter controlled double-blind study with a modified-release formulation. Chest 96:1252–1257PubMedGoogle Scholar
  34. 34.
    Müsken H, Wahl R, Franz J-Th, Masuch G, Sauter Ch, Bergmann K-Ch ((1996) Häufigkeit von Hausstaubmilben-Sensibilisierung. Allergologie 19:29–34Google Scholar
  35. 35.
    Nishioka K, Yasueda H, Saito H (1998) Preventive effect of bedding encasement with microfine fibers on mite sensitization. J Allergy Clin Immunol 101:28–32PubMedGoogle Scholar
  36. 36.
    Peat JK, Britton WJ, Salome CM, Woolcock AJ (1987) Bronchial hyperresponsiveness in two populations of Australian school children. III. Effect of exposure to environmental allergens. Clin Allergy 17:291–330PubMedGoogle Scholar
  37. 37.
    Platts-Mills TAE, Rovvey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR (1982) Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet III:675–678Google Scholar
  38. 38.
    Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R (2001) Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357:752–756PubMedCrossRefGoogle Scholar
  39. 39.
    Pürschel W ((1973) Dermatologische Klimatherapie an der Nordsee. Dermatologica 146[Suppl 1]:1–98PubMedGoogle Scholar
  40. 40.
    Ring J, Abeck D (1996) Vom “Patienten-Management” zum “Selbst-Management”: Prävention durch Schulung bei atopischem Ekzem (Neurodermitis). In: Stützner W, Giesler M (eds) Prävention allergischer Erkrankungen im Kindes-und Jugendalter. Kohlhammer, Stuttgart, pp 32–41Google Scholar
  41. 41.
    Ring J, Gfesser M (1997) Atopieprävention. In: Plewig G, Przybilla B (eds) Fortschritte der praktischen Dermatologie und Venerologie, vol 15. Springer, Berlin Heidelberg New York, pp 317–321Google Scholar
  42. 42.
    Ring J, Wenning J (eds) (2000) Weißbuch: Allergie in Deutschland 2000. Urban und Vogel, MunichGoogle Scholar
  43. 43.
    Ring J, Schäfer T (2001) Vernetzungsansätze in der Allergieforschung. In: Aktionsbündnis Allergieprävention. BMG, Bonn, pp 21–25Google Scholar
  44. 44.
    Saarinen U, Kajosaari M (1995) Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Lancet 346:1065–69PubMedGoogle Scholar
  45. 45.
    Schober G (1988) Feuchte und Entwicklung von Wohnungsallergenen. Allergologie 11:229–234Google Scholar
  46. 46.
    Schoenecker I, Grübl A, Bartels P, Ulm K, Bauer CP (2001) Klinische Effekte der Allergenreduktion durch Encasing — eine Metaanalyse. Allergy J 10:95–99Google Scholar
  47. 47.
    Schultze-Werninghaus (1993) Allergenkarenz bei inhalativer Allergie. In: Manuale allergologicum, VII.1, Dustri, Munich, pp 1–9Google Scholar
  48. 48.
    Stiftung Deutscher Polleninformationsdienst (1997) 1. Europäisches Pollenflug-Symposium. Verlag für Medizin und Umwelt, KrefeldGoogle Scholar
  49. 49.
    Stünzner W, Giesler M (eds) (1996) Prävention allergischer Erkrankungen im Kindes-und Jugendalter. XXIII. Kongreß der Deutschen Zentrale für Volksgesundheitspflege e.V. (DZV). Kohlhammer, StuttgartGoogle Scholar
  50. 50.
    Tan BB, Weald D, Strickland I, et al. (1996) Double-blind controlled trial of effect of housedustmite allergen avoidance on atopic dermatitis. Lancet 347:15–18PubMedGoogle Scholar
  51. 51.
    van Leeuwen S (1926) Allergische Krankheiten. Asthma bronchiale, Heufieber, Urticaria und andere. Dtsch Übers von Verzár F. Springer, Berlin Heidelberg New YorkGoogle Scholar
  52. 52.
    Vandenhove T, Soler M, Birnbaum J, Charpin D, Vervloet D (1993) Effect of dry cleaning on mite allergen levels in blankets. Allergy 48:264–266PubMedGoogle Scholar
  53. 53.
    Vervloet D, Penaud A, Razzouk H, Senft M, Arnaud A, Boutin C, Charpin J (1982) Altitude and house dust mites. J Allergy Clin Immunol 69:290–296PubMedGoogle Scholar
  54. 54.
    Vocks E, Borelli S, Rakoski J (1994) Klimatherapie bei Neurodermitis. Allergologie 17:208–213Google Scholar
  55. 55.
    Wahn U (1987) Möglichkeiten der Allergieprophylaxe bei Säuglingen und Kleinkindern. Allergologie 10:362–364Google Scholar
  56. 56.
    Wahn U, von Mutius E (2001) Childhood risk factors for atopy and the importance of early intervention. J Allergy Clin Immunol 107:567–574PubMedGoogle Scholar
  57. 57.
    Wanner H-U (1994) Biologische Verunreinigungen in der Raumluft. Allergologie 17:526–529Google Scholar
  58. 58.
    Wood RA, Chapman MD, Adkinson NF Jr, Eggleston PA (1989) The effect of cat removal on allergen content household dust samples. J Allergy Clin Immunol 83:730–734PubMedGoogle Scholar
  59. 59.
    Zock JP, Brunekreef B (1995) House dust mite allergen levels in dust from schools with smooth and carpeted classroom floors. Clin Exp Allergy 25:549–553PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations